Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Regeneron vs. Travere

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Regeneron's SG&A expenses surged by over 420%, peaking at approximately $2.63 billion in 2023. In contrast, Travere's expenses grew by around 345%, reaching about $266 million in the same year. Despite Regeneron's higher absolute costs, their growth rate indicates a strategic expansion, possibly reflecting increased investment in marketing and administration to support their growth trajectory. Meanwhile, Travere's more modest increase suggests a tighter control over their SG&A expenses, potentially focusing on efficiency and cost-effectiveness. This comparison highlights the diverse strategies employed by pharmaceutical companies in managing operational costs, each tailored to their unique business models and market positions.